Abstract

Although isoniazid (isonicotinic acid hydrazide, INH) is widely used for the treatment of tuberculosis, its molecular target has remained elusive. In response to INH treatment, saturated hexacosanoic acid (C26:0) accumulated on a 12-kilodalton acyl carrier protein (AcpM) that normally carried mycolic acid precursors as long as C50. A protein species purified from INH-treated Mycobacterium tuberculosis was shown to consist of a covalent complex of INH, AcpM, and a β-ketoacyl acyl carrier protein synthase, KasA. Amino acid–altering mutations in the KasA protein were identified in INH-resistant patient isolates that lacked other mutations associated with resistance to this drug.

Keywords

IsoniazidMycobacterium tuberculosisMicrobiologyIsonicotinic acidHydrazideTuberculosisBiochemistryChemistryBiologyMedicine

Affiliated Institutions

Related Publications

Publication Info

Year
1998
Type
article
Volume
280
Issue
5369
Pages
1607-1610
Citations
394
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

394
OpenAlex

Cite This

Khisimuzi Mdluli, Richard A. Slayden, Ya-Qi Zhu et al. (1998). Inhibition of a <i>Mycobacterium tuberculosis</i> β-Ketoacyl ACP Synthase by Isoniazid. Science , 280 (5369) , 1607-1610. https://doi.org/10.1126/science.280.5369.1607

Identifiers

DOI
10.1126/science.280.5369.1607